LONDON, April 20,
2022 /PRNewswire/ -- Hikma Pharmaceuticals PLC
(Hikma, Group), the multinational pharmaceutical group, today
confirms it has received preliminary approval from the US Federal
Trade Commission (FTC) and will now work towards closing its
acquisition of Custopharm Inc. from Water Street Healthcare
Partners, as previously announced on 27
September 2021. The parties have now obtained all regulatory
approvals required to close the transaction. Hikma will make a
further announcement upon the close of the transaction.
Enquiries:
Hikma
(Investors):
Susan
Ringdal
EVP, Strategic Planning
and Global Affairs
|
+44 (0)20 7399 2760/
+44 (0)7776 477050
|
Guy
Featherstone
Senior Investor
Relations
Manager
|
+44 (0)20 3892 4389/
+44 (0)7795 896738
|
Layan
Kalisse
Investor Relations
Analyst
|
+44 (0)20 7399 2788/
+44 (0)7970 709912
|
Teneo (Press):
Charles
Armitstead/Camilla Cunningham
US Media
Steven Weiss/David
Belian
|
+44 (0)7703 330 269/ +44 (0)7464
982426
+1 732 788 8279/ +1 848 254
4875
|
About Hikma
(LSE: HIK) (NASDAQ Dubai: HIK) (OTC:
HKMPY) (rated BBB-/stable S&P and BBB-/stable Fitch)
Hikma helps put better health within reach every day for
millions of people around the world. For more than 40 years, we've
been creating high-quality medicines and making them accessible to
the people who need them. Headquartered in the UK, we are a global
company with a local presence across the
United States (US), the Middle
East and North Africa
(MENA) and Europe, and we use our
unique insight and expertise to transform cutting-edge science into
innovative solutions that transform people's lives. We're committed
to our customers, and the people they care for, and by thinking
creatively and acting practically, we provide them with a broad
range of branded and non-branded generic medicines. Together, our
8,700 colleagues are helping to shape a healthier world that
enriches all our communities. We are a leading licensing partner,
and through our venture capital arm, are helping bring innovative
health technologies to people around the world. For more
information, please visit: www.hikma.com
View original
content:https://www.prnewswire.com/news-releases/hikma-confirms-ftc-preliminary-approval-for-custopharm-301528694.html
SOURCE Hikma Pharmaceuticals USA Inc.